Side-by-side · Research reference
CartalaxvsPNC-27
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED10/32 cited
BAnimal-StrongHUMAN-REVIEWED18/41 cited
Cartalax
Bioregulator Peptide · Khavinson School
SQ · Protocol Unspecified
PNC-27
p53-HDM-2 Peptide · Membrane-Targeting
In vitro / Pre-clinical only
01Mechanism of Action
Parameter
Cartalax
PNC-27
Primary target
Mesenchymal stem cells (MSCs) undergoing chondrogenic differentiationLinkova 2023
Membrane-bound HDM-2 protein on cancer cell surfaceSarafraz-Yazdi 2022Krzesaj 2024
Pathway
Modulation of WNT, ERK-p38, and Smad 1/5/8 signaling pathwaysLinkova 2023
PNC-27 binds to membrane HDM-2 1-109 domain → transmembrane pore formation → rapid necrosis (poptosis)Pincus 2024Krzesaj 2024
Downstream effect
Upregulation of chondrogenic genes (COL2, SOX9, ACAN); increased bone mineral density; osteoprotective effects in ovariectomy-induced osteoporosisLinkova 2023Povorozniuk 2007
Immediate cell lysis and extrusion of intracellular contents; secondary mitochondrial membrane disruptionPincus 2024Krzesaj 2024
Feedback intact?
—
N/A — cytotoxic mechanism, not signaling modulation
Origin
Derived from cartilaginous tissue extracts (Khavinson bioregulator methodology)Povorozniuk 2007
Chimeric design: p53 transactivating domain (12-26) fused to penetratin CPP sequenceSarafraz-Yazdi 2022
Antibody development
—
—
02Dosage Protocols
Parameter
Cartalax
PNC-27
Animal model dose
Unspecified (cartilaginous tissue extract protocol)
Rat study; extract preparation details not indexed in available abstracts.
—
Human dosing
Not established in PubMed-indexed literature
Russian-tradition protocols exist but lack peer-reviewed Western validation.
—
Evidence basis
Animal mechanistic studies only
Pre-clinical / In vitro
Clinical status
—
Pre-clinical only — no human trials
In vitro and animal model data only.
In vitro concentrations
—
10–100 μM range
Effective concentrations in cell culture studies.
Shorter analogue
—
PNC-28 (28 AA variant)
Retains HDM-2 binding and cytotoxic activity.
03Metabolic / Fat Loss Evidence
Parameter
Cartalax
PNC-27
Fat loss evidence
None — primary target is cartilage and bone tissue, not adipose
—
Fat loss mechanism
—
None — cytotoxic anticancer agent
04Side Effects & Safety
Parameter
Cartalax
PNC-27
Documented adverse effects
None reported in indexed animal studies
—
Human safety data
Not available in PubMed-indexed literature
None available — no human trials conducted
Normal cell selectivity
—
In vitro: no cytotoxicity to normal cells (MCF-10-2A, peripheral blood mononuclear cells)Sarafraz-Yazdi 2010Thadi 2020
Normal cells express minimal membrane HDM-2.
Cancer cell specificity
—
Depends on membrane HDM-2 expression levels
Ovarian cancer lines with low membrane HDM-2 showed <30% necrosis.
Mitochondrial effects
—
Secondary mitochondrial membrane disruption in cancer cells
Absolute Contraindications
Cartalax
- ·Unknown due to lack of human clinical trial data
PNC-27
- ·Human use — no clinical trials or safety data
Relative Contraindications
Cartalax
- ·Active malignancy (theoretical; peptide bioregulators may influence cell proliferation pathways)
PNC-27
—05Administration Protocol
Parameter
Cartalax
PNC-27
1. Route
Subcutaneous injection typical for Khavinson bioregulators; specific protocols not detailed in indexed literature.
PNC-27 has not been tested in human subjects. All data derive from in vitro cancer cell line studies and limited animal models. No approved clinical formulation, dosing protocol, or safety profile exists.Pincus 2024
2. Frequency
Russian-tradition protocols often employ 10-day cycles; precise frequency unspecified in available abstracts.
In vitro studies used 10–100 μM PNC-27 dissolved in cell culture medium. Peptide was added directly to cancer cell cultures (pancreatic, breast, colon, ovarian, leukemia lines) and incubated for 24–72 hours.
3. Storage
Lyophilised peptide bioregulators typically stored at 2–8 °C, light-protected. Reconstitution details not indexed.
Dual-labeled PNC-27 (green on N-terminus, red on C-terminus) demonstrated intact peptide binding to cancer cell membranes with combined yellow fluorescence at 30 minutes, persisting during cell lysis.Sookraj 2010
4. Membrane HDM-2 requirement
—
Cytotoxicity correlates directly with membrane HDM-2 expression levels. Blocking HDM-2's p53-binding domain (1-109) with monoclonal antibodies prevents PNC-27-induced necrosis.